Market Cap 261.78M
Revenue (ttm) 49.22M
Net Income (ttm) -36.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.69%
Debt to Equity Ratio 0.81
Volume 63,100
Avg Vol 151,856
Day's Range N/A - N/A
Shares Out 55.58M
Stochastic %K 37%
Beta 2.82
Analysts Strong Sell
Price Target $7.20

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 81 69 16 00
Address:
8, rue de la Croix Jarry, Paris, France
rlkloehn
rlkloehn Dec. 1 at 6:11 PM
$CLLS On December 4, Cellectis is hosting a webinar dedicated to French shareholders to provide an update on our recent scientific, clinical and strategic developments, including: 📍 The promising Phase 1 clinical data presented at the R&D Day on October 16, 2025 for lasme-cel, as well as the pivotal Phase 2 design. 📍The commercial potential of lasmé-cel (up to approximately $700 million in annual gross sales at its peak). 📍The next steps for our eti-cel. 📍A review of our strategic partnerships. 📍Our recent advances in genome editing. The presentation will be followed by a Q&A session with the executives. ❓ Submit your questions in advance to: mailto:[email protected] 👉 Registration required – link in first comment.
1 · Reply
AnomalyDetective
AnomalyDetective Nov. 29 at 8:55 PM
All new MDA breakout picks out for Week 49 with momentum gauges improving sharply. 💥 Last week the minimum returns of +17.59% beat the full year #SPX $SPY YTD returns +17.47% through 48 weeks. 💥 Week 48 MDA picks $PSNL $TNGX $ZYME $CLLS all broke 10% gains in the short trading week. New picks for next week. 👉 New selections here with only 3 full weeks of trading before prices increase for 2026! See the 93 picks in the past year gaining over 20% from selection: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6231448-december-mda-breakout-stocks-week-49-and-highlighted-top-gainers
0 · Reply
mikefbi
mikefbi Nov. 24 at 9:12 PM
$CLLS Slowly reducing my position...Huge profit Cash is king
0 · Reply
AnomalyDetective
AnomalyDetective Nov. 24 at 12:49 PM
$CLLS up another 10% premarket for members as the Week 48 MDA picks gain +10.22% with 3 out of 4 selections on track over 10% gains to start the short trading week. Selections extending the count to 346 weeks with at least one pick gain over 10% in less than a week. See prior chart on $TNGX and many more prior mda breakout stocks at http://top.vmbreakouts.com @VMBreakouts
0 · Reply
AnomalyDetective
AnomalyDetective Nov. 20 at 1:50 PM
$CLLS in MDA breakout Segment 6 positive acceleration from last week moving higher again premarket. Credit: http://vmbreakouts.com @vmbreakouts
0 · Reply
DARKP00L
DARKP00L Nov. 19 at 7:28 PM
$CLLS 14:12 on Nov. 19 2025 Why Cellectis Stock Is Trading Higher Today #tradeideas
0 · Reply
mikefbi
mikefbi Nov. 19 at 2:27 PM
$CLLS Still
0 · Reply
jackblack77
jackblack77 Nov. 15 at 12:14 PM
$CLLS Hot on the horizon! In December, news for Cellectis should be strong, and the stock will be heavily traded. - On December 15th, the Servier vs. Cellectis arbitration was finalized, with Cellectis receiving hundreds of millions of dollars in compensation. - On December 7th, Cellectis announced the acceptance of an abstract for Lasme-Cel for poster presentation at the 2025 Annual Meeting of the American Society of Hematology (ASH).
1 · Reply
mikefbi
mikefbi Nov. 14 at 8:52 PM
$CLLS Reducing position huge profit ...
0 · Reply
DarthTrader75
DarthTrader75 Nov. 14 at 8:20 PM
$CLLS Gem - nice figures and solid numbers. Looking forward to the next 3-6 months!
0 · Reply
Latest News on CLLS
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 11:50 AM EDT - 4 months ago

Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript


Cellectis Reports Financial Results for the First Quarter 2025

May 12, 2025, 4:30 PM EDT - 7 months ago

Cellectis Reports Financial Results for the First Quarter 2025


Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Mar 14, 2025, 10:36 AM EDT - 9 months ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript


Cellectis: Poised To Start Answering Questions In 2025

Dec 12, 2024, 3:08 PM EST - 1 year ago

Cellectis: Poised To Start Answering Questions In 2025


Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 1:59 PM EST - 1 year ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript


Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 2:06 PM EDT - 1 year ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript


Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Financial Results for First Quarter 2024


rlkloehn
rlkloehn Dec. 1 at 6:11 PM
$CLLS On December 4, Cellectis is hosting a webinar dedicated to French shareholders to provide an update on our recent scientific, clinical and strategic developments, including: 📍 The promising Phase 1 clinical data presented at the R&D Day on October 16, 2025 for lasme-cel, as well as the pivotal Phase 2 design. 📍The commercial potential of lasmé-cel (up to approximately $700 million in annual gross sales at its peak). 📍The next steps for our eti-cel. 📍A review of our strategic partnerships. 📍Our recent advances in genome editing. The presentation will be followed by a Q&A session with the executives. ❓ Submit your questions in advance to: mailto:[email protected] 👉 Registration required – link in first comment.
1 · Reply
AnomalyDetective
AnomalyDetective Nov. 29 at 8:55 PM
All new MDA breakout picks out for Week 49 with momentum gauges improving sharply. 💥 Last week the minimum returns of +17.59% beat the full year #SPX $SPY YTD returns +17.47% through 48 weeks. 💥 Week 48 MDA picks $PSNL $TNGX $ZYME $CLLS all broke 10% gains in the short trading week. New picks for next week. 👉 New selections here with only 3 full weeks of trading before prices increase for 2026! See the 93 picks in the past year gaining over 20% from selection: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6231448-december-mda-breakout-stocks-week-49-and-highlighted-top-gainers
0 · Reply
mikefbi
mikefbi Nov. 24 at 9:12 PM
$CLLS Slowly reducing my position...Huge profit Cash is king
0 · Reply
AnomalyDetective
AnomalyDetective Nov. 24 at 12:49 PM
$CLLS up another 10% premarket for members as the Week 48 MDA picks gain +10.22% with 3 out of 4 selections on track over 10% gains to start the short trading week. Selections extending the count to 346 weeks with at least one pick gain over 10% in less than a week. See prior chart on $TNGX and many more prior mda breakout stocks at http://top.vmbreakouts.com @VMBreakouts
0 · Reply
AnomalyDetective
AnomalyDetective Nov. 20 at 1:50 PM
$CLLS in MDA breakout Segment 6 positive acceleration from last week moving higher again premarket. Credit: http://vmbreakouts.com @vmbreakouts
0 · Reply
DARKP00L
DARKP00L Nov. 19 at 7:28 PM
$CLLS 14:12 on Nov. 19 2025 Why Cellectis Stock Is Trading Higher Today #tradeideas
0 · Reply
mikefbi
mikefbi Nov. 19 at 2:27 PM
$CLLS Still
0 · Reply
jackblack77
jackblack77 Nov. 15 at 12:14 PM
$CLLS Hot on the horizon! In December, news for Cellectis should be strong, and the stock will be heavily traded. - On December 15th, the Servier vs. Cellectis arbitration was finalized, with Cellectis receiving hundreds of millions of dollars in compensation. - On December 7th, Cellectis announced the acceptance of an abstract for Lasme-Cel for poster presentation at the 2025 Annual Meeting of the American Society of Hematology (ASH).
1 · Reply
mikefbi
mikefbi Nov. 14 at 8:52 PM
$CLLS Reducing position huge profit ...
0 · Reply
DarthTrader75
DarthTrader75 Nov. 14 at 8:20 PM
$CLLS Gem - nice figures and solid numbers. Looking forward to the next 3-6 months!
0 · Reply
aletz
aletz Nov. 13 at 3:35 PM
$CLLS https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ Another French gem, ranked 10th this week on my AI scanner list, very strong science, well funded, very promising.
0 · Reply
mikefbi
mikefbi Nov. 11 at 3:19 PM
$CLLS Great Company Super Profit Still
0 · Reply
aletz
aletz Nov. 6 at 9:36 PM
$CLLS https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #15 on the list
0 · Reply
rlkloehn
rlkloehn Nov. 5 at 7:38 PM
$CLLS On November 12, join Cellectis at Baird’s Biotech Discovery Series. Our CEO Andre Choulika Ph.D., and our CMO Dr. Adrian Kilcoyne MD MPH MBA, will share the latest Phase 1 results from the BALLI-01 study of lasme-cel - our allogeneic CD22 CAR-T candidate for patients with relapsed or refractory B-ALL.
1 · Reply
metalcook
metalcook Nov. 4 at 9:24 PM
$CRBU $ALLO $CLLS ALL worth around 200mil$.. market is treating allogemic therapy as one and does not want ascribe any value for the data available.
1 · Reply
rlkloehn
rlkloehn Nov. 3 at 3:23 PM
$CLLS "The evolution of eti-cel marks an important milestone, with the addition of IL-2 that could encourage the preliminary responses already observed in our Phase 1 study," said Adrian Kilcoyne, MD, MPH, MBA, Medical Director of Cellectis. "We look forward to sharing all the Phase 1 data including those from the cohorts with IL-2, whose presentation is expected in 2026".
2 · Reply
rlkloehn
rlkloehn Nov. 3 at 2:25 PM
$CLLS NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company, which uses its pioneering genome editing platform to develop innovative cell and gene therapies for the treatment of serious diseases, announced today that two abstracts have been selected for a poster presentation at the annual convention of the American Society of Hematology (ASH) 2025, which will be held from December 6 to 9, 2025 in Orlando.
0 · Reply
mikefbi
mikefbi Oct. 27 at 10:31 PM
$CLLS Patients
0 · Reply
IsabelSims1079
IsabelSims1079 Oct. 20 at 4:28 PM
$CLLS engineering immune therapies; AITX engineering enterprise AI — profitability plus expanding SARA visibility highlight discipline.
0 · Reply
PaulLaurent
PaulLaurent Oct. 19 at 4:33 PM
🧭 Weekly Swing Recap — October 19, 2025 $EVAX – +102% from our entry zone — swing winner this week. Clean trend; trims into strength worked. $KOPN – +35% from our entry zone — exceeded the profit target. $GANX – Profit target hit but required fast execution; otherwise breakeven. $CHEK – +21% from our entry zone — profit zone reached. $CLLS – +37% from our entry zone — profit zone reached. Tone: Solid week for swings. Keep prioritizing VWAP or pivot reclaims, scale out into strength, and protect gains with tight risk if momentum cools.
1 · Reply
JLynneB51671
JLynneB51671 Oct. 19 at 3:53 PM
$PRQR $CLLS $RYOJ Hey Y'all- PSA- Jay truly is for real!!! Jay is remarkable. He's not looking for personal gain in the least! We in his group have benefited galaxies above and beyond. Not only from trade notifications, but detailed, personalized advice, knowledge, and support. We keep growing everyday! It's a community void of any ulterior motive other than helping and supporting each other to not only make bank, but to genuinely lift up others overall. The ONLY thing Jay requests for in return is to pay it forward, to any degree you can. Most importantly is to support his true life's mission; to give back to the cancer fighting community. So there it is. GLTA!!! 🙏💙🙏 *this is a "testimonial" given of my own accord, btw, as a member of his community.
1 · Reply
anachartanalyst
anachartanalyst Oct. 17 at 2:02 PM
$CLLS https://anachart.com/wp-content/uploads/ana_temp/1760709735_soc-img.jpg
0 · Reply